# Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

> **NCT00100906** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 18 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** IL-2
- **DRUG:** ATRA

## Key facts

- **NCT ID:** NCT00100906
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2006-06
- **Final completion:** 2013-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2013-08-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00100906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00100906, "Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00100906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*